- Home
- SHMD vs ADAG Comparison
SHMD vs ADAG Comparison
Compare SHMD & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHMD
- ADAG
- Stock Information
- Founded
- SHMD 1864
- ADAG 2011
- Country
- SHMD Germany
- ADAG China
- Employees
- SHMD N/A
- ADAG N/A
- Industry
- SHMD
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- SHMD
- ADAG Health Care
- Exchange
- SHMD Nasdaq
- ADAG Nasdaq
- Market Cap
- SHMD 100.8M
- ADAG 91.2M
- IPO Year
- SHMD N/A
- ADAG 2021
- Fundamental
- Price
- SHMD $3.25
- ADAG $2.05
- Analyst Decision
- SHMD
- ADAG Strong Buy
- Analyst Count
- SHMD 0
- ADAG 1
- Target Price
- SHMD N/A
- ADAG $5.00
- AVG Volume (30 Days)
- SHMD 58.0K
- ADAG 88.5K
- Earning Date
- SHMD 12-31-2024
- ADAG 07-25-2024
- Dividend Yield
- SHMD N/A
- ADAG N/A
- EPS Growth
- SHMD 1309.32
- ADAG N/A
- EPS
- SHMD 1.07
- ADAG N/A
- Revenue
- SHMD $99,752,404.00
- ADAG $815,746.00
- Revenue This Year
- SHMD N/A
- ADAG N/A
- Revenue Next Year
- SHMD N/A
- ADAG $2.70
- P/E Ratio
- SHMD $3.09
- ADAG N/A
- Revenue Growth
- SHMD N/A
- ADAG N/A
- 52 Week Low
- SHMD $1.98
- ADAG $1.60
- 52 Week High
- SHMD $6.13
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- SHMD N/A
- ADAG 43.59
- Support Level
- SHMD N/A
- ADAG $2.02
- Resistance Level
- SHMD N/A
- ADAG $2.15
- Average True Range (ATR)
- SHMD 0.00
- ADAG 0.24
- MACD
- SHMD 0.00
- ADAG -0.00
- Stochastic Oscillator
- SHMD 0.00
- ADAG 21.87
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.